Redeye comments on Avensia’s October sales figures.
Redeye returns with an update following AlzeCure’s Q3 earnings release, which aligned with our expec...
OXE Marine just announced a development agreement with GM Marine for the next generation of OXE outb...
Redeye comments on Dala Energi’s Q3 report, which presented no real surprises.
* Q3 was softer, but better cost control was positive * '25e-'27e sales cut by 15-22% on lower volum...
Redeye provides an initial take following Paxman’s Q3 2025 report.
Redeye provides a note following Guard’s Q3 report, which aligned with our expectations.
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Redeye updates on Better Collective after its Q3-report where leave our estimates largely unchanged ...
Redeye views the Q3 report as solid, with sales slightly ahead of expectations and tighter cost cont...
Redeye updates its estimates following Surgical Science’s Q3 2025 report, which featured decent sale...
Fable Media Group delivered a soft Q3 in line with the preliminary figures, but the underlying trend...
Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.
Envar rapporterade för det tredje kvartalet 2025 en nettoomsättning om 27,2 MSEK (22,2), motsvarande...
* Better-than-expected Q3 earnings, all segments up q-o-q * We raise our EBIT estimates by 4-3% for ...
Redeye provides its comment on Mendus’ Q3 2025 report.
* Q3 a bump in the road * Estimates down given more cautious view on activity pick-up * 2025e-'27e E...
Redeye provides a research update following the Q3 report published by Alzinova earlier today.
Omsättningen kom in linje med Analysguidens estimat och uppgick till 7,9 (9,7) meur, varav PremierGa...
EQL Pharma redovisade ett svagare andra kvartal 2025/26, påverkat av leveransstörningar som tillfäll...
